Patheon IncTSX: PTI

Patheon completes preferred share agreement amendment

· Issued by Patheon Inc via CNW

TORONTO, Sept. 19 /CNW/ - Patheon (TSX:PTI) today announced the completion of the agreement with JLL Patheon Holdings, LLC ("JLL") that was previously announced September 5, 2008 and under which JLL has waived its right to the mandatory redemption provision of the Company's convertible preferred shares. In accordance with the terms of the agreement Patheon has issued 400,000 restricted voting shares to JLL and has granted JLL a limited waiver of the standstill provision under the investor agreement, which will allow JLL to acquire restricted voting shares in the open market over the next twelve months equal to no more than 1% of the equity of the Company, including the restricted voting shares issuable under the convertible preferred shares. Additional details on the Agreement can be found in the Company's third quarter MD&A filed with SEDAR at www.sedar.com.

ABOUT PATHEON

Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.

Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.

Patheon's integrated development and manufacturing network of 11 facilities, and 6 development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

Caution Concerning Forward-Looking Statements

This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

%SEDAR: 00001700E

Patheon Inc on 6ix

Earlier from Patheon

Later from Patheon

All Patheon news releases